Ceftriaxone/remdesivir/sodium chlorideLack of efficacy and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1918卷 / 1期

关键词：

D O I：

10.1007/s40278-022-20594-3

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：137 / 137

相关论文

共 50 条

[21] Ceftriaxone/norepinephrine/sodium-chlorideLack of efficacy: case report
Reactions Weekly, 2022, 1922 (1) : 174 - 174
[22] Caspofungin/ceftriaxone/hydroxychloroquineBrugada syndrome and off-label use: case report
Reactions Weekly, 2021, 1861 (1) : 89 - 89
[23] COVID-19-vaccine/Ceftriaxone/RemdesivirLack of efficacy and off-label use: case report
Reactions Weekly, 2024, 2026 (1) : 101 - 101
[24] Enoxaparin-sodium/methylprednisoloneLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1934 (1) : 181 - 181
[25] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1866 (1) : 47 - 47
[26] BevacizumabLack of efficacy and off-label use: case report
Reactions Weekly, 2025, 2042 (1) : 81 - 81
[27] AcetylcysteineLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1900 (1) : 16 - 16
[28] AntineoplasticsLack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1838 (1) : 56 - 56
[29] DexamethasoneLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1910 (1) : 178 - 178
[30] HydroxychloroquineLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1925 (1) : 264 - 264

← 1 2 3 4 5 →